Meeder Advisory Services Inc. Buys New Shares in Becton, Dickinson and Company $BDX

Meeder Advisory Services Inc. purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the second quarter, Holdings Channel reports. The firm purchased 3,323 shares of the medical instruments supplier’s stock, valued at approximately $503,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Imprint Wealth LLC purchased a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at about $25,000. SHP Wealth Management bought a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $26,000. Meeder Asset Management Inc. boosted its stake in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 102 shares in the last quarter. Main Street Group LTD bought a new position in Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Finally, Bell Investment Advisors Inc purchased a new position in shares of Becton, Dickinson and Company during the second quarter worth approximately $29,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 11,779 shares of company stock worth $1,974,669 over the last quarter. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.1%

Shares of NYSE:BDX opened at $187.79 on Friday. The stock’s 50-day moving average is $160.66 and its 200 day moving average is $160.91. The company has a market cap of $51.74 billion, a PE ratio of 56.56, a P/E/G ratio of 13.22 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $190.01.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business’s revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the business posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is 126.51%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Piper Sandler boosted their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Wells Fargo & Company lifted their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. TD Cowen upped their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Finally, Bank of America reduced their price objective on Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $185.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.